Carotid plaques treated with Bembedoic acid: a 7% of reduction in 6 months
Open accessAbstract
Abstract Bempedoic acid were indicated to be able to reduce the hypercholesterolemia add on to statin and ezetimibe therapy. We investigated the effect of the same treatment in carotid atherosclerosis after a follow up of 6 months. Methods A continuous series of 22 patients were enrolled in a prospective analysis. All patients started a therapy with bempedoic acid for hypercholesterolemia add on to rosuvastatin or atorvastatin plus ezetimibe therapy for an insufficient reduction of cholesterol. The mean of LDL dosage was 101 mg/dl. All patients were high or very high-risk patient. In all patients the bempedoic acid was added to optimal medical therapy without new symptoms in ambulatory. The recruitment period was long 1 month. After the recruitment the patient was follow for other 6 month. At the start and at the end of the follow-up we evaluated. The atherosclerosis was evaluated in an ultrasound doppler of carotids The data was collect in excel and analysed by the Q-R-Calc program. Results The mean age of patients was 68 age, 44% female. 33% was diabetic patients. Hypertension was present in 73%, hypercholesterolemia in 100%. 11% was smokers. 94% were Caucasian patients. The mean of Weight was 75 kg at the first control. The mean height 174 cm. All patients performed a cardiological control in which the medical doctor prescribed bempedoic acid. 100% of patients assumed a statin, 100% ezetimibe. After 6 month the mean LDL was 78 mg/dl. The doppler showed plaques in 89% of pa…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In two studies of patients with ASCVD on maximum dose rosuvastatin plus ezetimibe or rosuvastatin/atorvastatin plus ezetimibe, initiation of bempedoic acid achieved LDL-C reductions of 29.1% to 39.0% at 6 months.
“In these studies, the initiation of bempedoic acid achieved LDL-C reductions of 29.1% (baseline LDL-C = 100 mg/dL) to 39.0% (baseline LDL-C = 130 mg/dL) at 6 months’ follow-up [32,38].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [32]
LDL-C reductions with bempedoic acid added to statins ranged from 15% to 39%.
“Consistent effects were also seen when bempedoic acid was added to statins (15% to 39%) [25,30,32,38,39,44], and when used in statin intolerant patients (22% to 38%) [24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [32]
Real-world LDL-C reductions with bempedoic acid in secondary prevention populations ranged from 15% to 39%.
“These reductions were reported across both primary (23% to 39%) [24,29,44] and secondary prevention populations (15% to 39%) [25,32,38,39].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [32]
Cites
Still being checked.
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
- Authors
- Fazio, G.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Fazio, G
- ORCID
- Fazio, G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-05
- Volume
- 122
- Issue
- Supplement_1
- Pages
- ii114-ii115
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W4396969461
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cardiovascular Research (publishedVersion)
- European Heart Journal Supplements (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cerebrovascular and Carotid Artery Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- bempedoic acid, carotid atherosclerosis, hypercholesterolemia, statin therapy, ezetimibe, rosuvastatin, atorvastatin, LDL cholesterol, Doppler ultrasound, high-risk patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
